Another BCL-2-specific inhibitor venetoclax, demonstrated efficacy in SCLC cell lines expressing high levels of BCL-2 [79] and a phase I trial of venetoclax together with ABBV-075, a bromodomain and extra-terminal domain (BET) inhibitor, is currently under way (NCT02391480). This evidence concerns the gene BCL2 and small cell lung carcinoma.